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Review: several interventions prevent ventilator
associated pneumonia in critically ill patients
Collard HR, Saint S,Matthay MA.Prevention of ventilator-associated pneumonia: an evidence-based systematic review.
Ann Intern Med 2003;138:494–501.
QUESTION: Which interventions prevent ventilator associated pneumonia (VAP) in
critically ill patients?
Data sources
English language studies were identified by searching
Medline (1966–2001) and the Cochrane Library, and by
reviewing bibliographies of retrieved articles.
Study selection
Studies were selected if they were randomised control-
led trials (RCTs) or observational cohort controlled
trials.
Data extraction
Data were extracted on study design, intervention, and
outcomes.
Main results
34 studies met the selection criteria.Meta-analysis was not
done because of study variations in the diagnostic criteria
for pneumonia. Results are summarised in the table.
Conclusions
Semirecumbent positioning, stress ulcer prophylaxis
(sucralfate rather than H2 antagonists), aspiration of
subglottic secretions, selective digestive tract decontami-
nation, and oscillating beds reduce ventilator associated
pneumonia (VAP) in select critically ill patients. No evi-
dence currently supports specific methods of enteral
feeding or increased frequency of ventilator circuitry
changes for prevention of VAP.
Effectiveness of interventions for preventing ventilator associated pneumonia (VAP) in critically ill patients*
Intervention Results
Semirecumbent v supine positioning† (3 trials, n=116) ↓ VAP (1 RCT, n=86); ↓ gastroesophageal reﬂux and aspiration events (2 controlled
clinical trials, n=30); no difference in mortality (1 RCT, n=86)
Stress ulcer prophylaxis:
sucralfate v H2 antagonists (7 MAs of >20 RCTs; 1 recent RCT, n=1200)
↓ VAP (4 of 7 MAs), 3 MAs found no difference; ↓ mortality (3 of 4 MAs); equivocal
evidence regarding increased gastrointestinal bleeding (2 MAs), 1 recent RCT
(n=1200) found increased bleeding
Aspiration of subglottic secretions v none† (3 RCTs, n=641) no difference in VAP (2 RCTs, n=496), reduced VAP (1 RCT, n=145), delayed time to
VAP development (3 RCTs, n=641); no difference in mortality (3 RCTs, n=641)
Oscillating v standard non-oscillating beds† (1 MA of 6 RCTs; 1 recent RCT, n=103) ↓ pneumonia (1 MA), no difference (1 RCT, n=103); no difference in mortality (1 MA, 1
RCT, n=103)
Selective digestive tract decontamination v none† (7 MAs of >40 RCTs) ↓ VAP (7 MAs); ↓ mortality (4 of 7 MAs)
Topical + systemic antibiotics v none† ↓ VAP (3 of 3 MAs); ↓ mortality (4 of 4 MAs)
Topical antibiotics alone v none† ↓ VAP (3 of 3 MAs); no difference in mortality (4 of 4 MAs)
Ventilator circuit management (4 RCTs, n=NA)
Fewer v more changes (4 RCTs) no difference in VAP (4 RCTs)
Fewer v more changes in heat and moisture exchangers (1 RCT) no difference in VAP (1 RCT)
Heat and moisture exchanger v humidiﬁer (1 MA of 5 RCTs) no difference in VAP (4 of 5 RCTs in 1 MA); no difference in mortality (4 of 4 RCTs in 1 MA)
Enteral feeding methods (4 RCTs, n=504)
Small intestinal v gastric feeding no difference in VAP or mortality (1 RCT, n=44)
Metoclopramide v none† no difference in VAP or mortality (1 RCT, n=305)
Acidiﬁed v normal feedings† no difference in VAP or mortality (1 RCT, n=95)
Intermittent v continuous feeding no difference in VAP or mortality (1 RCT, n=60)
*RCT = randomised controlled trial, MA = meta-analysis, NA = not available.
†Information on comparison group provided by author.
COMMENTARY
VAP is a common condition among critically ill patients and a burden to healthcare systems. Although the incidence of VAP is difficult to determine because
of diagnostic variability, research shows a 20–30% mortality rate,1 longer ICU and hospital stays, and higher hospital costs for patients with VAP.2
The systematic review by Collard et al provides a thorough analysis of the evidence to date, highlighting the considerable gaps in our knowledge. In select-
ing studies for inclusion, the authors noted the lack of standardised diagnostic criteria, which prevented pooling of individual study results in a meta-analysis.
Diagnostic criteria for VAP may include fever, leukocytosis, purulent secretions, and changes on chest radiography and microbiology. Limitations of existing
studies included small sample sizes, lack of power, and equivocal and conflicting findings.
Although semirecumbent positioning of all eligible patients appears easy, inexpensive, and relatively uncontroversial, evidence on practices such as oscil-
lation beds and selective digestive decontamination is equivocal. Collard et al correctly attributed these conflicting findings to differences in inclusion crite-
ria, outcome measures, and analyses used in individual studies. They also caution practitioners about the use of selective digestive tract decontamination
because of uncertainties about effects of such treatment on antibiotic resistance, although no additional evidence to support this was included in the review.
Although cost may be a barrier for many of these practices, it is important to educate clinicians to take measures to prevent and recognise symptoms, and
diagnose VAP. Collard et al also noted that to date, no RCT has evaluated the effectiveness of combined preventative practices. Given the high mortality rate
associated with VAP, this research should be a priority.
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